Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
This study has been terminated.
( Withdrawal of marketing autorization of efalizumab by the EMEA. )
Study NCT00608777
Information provided by Derm Research, PLLC
First Received: January 23, 2008
Last Updated: March 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
